Development of Covalent Inhibitors That Can Overcome Resistance to First-Generation FGFR Kinase Inhibitors

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.1403438111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Development of Selective Covalent Janus Kinase 3 Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

Cancer Research
Cancer ResearchOncology
2019English

Resistance to PARP Inhibitors by SLFN11 Inactivation Can Be Overcome by ATR Inhibition

Oncotarget
Oncology
2016English

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance

Cancers
Cancer ResearchOncology
2018English

Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2014English

Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2013English

Overcoming Resistance to First/Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and ALK Inhibitors in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer

Therapeutic Advances in Medical Oncology
Oncology
2016English

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2011English

Covalent JNK Inhibitors?

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy